← All trials
NCT05429398
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Aug 31, 2023
- Completion date
- May 30, 2024
- First posted
- Jun 23, 2022
- Last posted
- Jun 23, 2022
- Enrollment
- 118
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai YingLi Pharmaceutical Co. Ltd.Lead sponsor
- Sun Yat-Sen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.